TY - JOUR
T1 - Acceptability, barriers and facilitators of using dried blood spots-point-of-care testing for sickle cell disease in Africa
T2 - an implementation science protocol for a multinational qualitative study
AU - On behalf of the SickleInAfrica Consortium
AU - Nnodu, Obiageli Eunice
AU - Munung, Nchangwi Syntia
AU - Chirande, Lulu
AU - Chunda-Liyoka, Catherine
AU - Kiguli, Sarah
AU - Sarfo, Fred Stephen
AU - Touré, Boubacari Ali
AU - Balandya, Emmanuel
AU - Guindo, Aldiouma
AU - Kuona, Patience
AU - Esoh, Kevin
AU - Jonas, Mario
AU - Nwegbu, Maxwell
AU - Masamu, Upendo
AU - Morrice, Jack
AU - Moru, Patrick Ohiani
AU - Bitoungui, Valentina Ngo
AU - Nembaware, Victoria
AU - Nkya, Siana
AU - Tshilolo, Léon
AU - Makani, Julie
AU - Wonkam, Ambroise
AU - Peprah, Emmanuel
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2024.
PY - 2024/11/7
Y1 - 2024/11/7
N2 - Background Sickle cell disease (SCD) is a prevalent inherited blood disorder. Globally, approximately 515 000 babies are born with SCD annually, with 75% of these births occurring in Africa. Integrating newborn screening (NBS) for SCD into primary healthcare structures, such as immunisation programmes, holds significant promise, with dried blood spots (DBS)-point-of-care technologies (POCT) like HaemoTypeSC offering cost-effective screening solutions. However, scaling up DBS-POCT for NBS of SCD in Africa remains challenging. Objective This study aims to explore individual, organisational and external factors that may influence the reliability, feasibility, acceptability, adoption and sustainability of using DBS-POCT with HaemoTypeSC for NBS of SCD at primary healthcare centres in African countries. Method This qualitative study will be conducted in seven African countries that are part of the SickleInAfrica consortium sites. The study design is informed by the Consolidated Framework for Implementation Research (CFIR) and the Implementation Outcome Model. Participants will be mothers whose babies have been diagnosed with SCD, healthcare professionals and policy-makers. In-depth interviews and focus group discussions will be used for data collection. Data analysis will be through thematic analysis. Ethics and dissemination Research ethics approvals have been obtained from the seven countries. Written informed consent will be obtained from all participants. The study results will be disseminated in peer-reviewed scientific journals, scientific conferences, reports to national ministries of public health and webinars.
AB - Background Sickle cell disease (SCD) is a prevalent inherited blood disorder. Globally, approximately 515 000 babies are born with SCD annually, with 75% of these births occurring in Africa. Integrating newborn screening (NBS) for SCD into primary healthcare structures, such as immunisation programmes, holds significant promise, with dried blood spots (DBS)-point-of-care technologies (POCT) like HaemoTypeSC offering cost-effective screening solutions. However, scaling up DBS-POCT for NBS of SCD in Africa remains challenging. Objective This study aims to explore individual, organisational and external factors that may influence the reliability, feasibility, acceptability, adoption and sustainability of using DBS-POCT with HaemoTypeSC for NBS of SCD at primary healthcare centres in African countries. Method This qualitative study will be conducted in seven African countries that are part of the SickleInAfrica consortium sites. The study design is informed by the Consolidated Framework for Implementation Research (CFIR) and the Implementation Outcome Model. Participants will be mothers whose babies have been diagnosed with SCD, healthcare professionals and policy-makers. In-depth interviews and focus group discussions will be used for data collection. Data analysis will be through thematic analysis. Ethics and dissemination Research ethics approvals have been obtained from the seven countries. Written informed consent will be obtained from all participants. The study results will be disseminated in peer-reviewed scientific journals, scientific conferences, reports to national ministries of public health and webinars.
KW - Haematopathology
KW - Implementation Science
KW - PAEDIATRICS
KW - Parents
UR - http://www.scopus.com/inward/record.url?scp=85209484126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85209484126&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2024-089056
DO - 10.1136/bmjopen-2024-089056
M3 - Article
C2 - 39515852
AN - SCOPUS:85209484126
SN - 2044-6055
VL - 14
JO - BMJ open
JF - BMJ open
IS - 11
M1 - e089056
ER -